🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,041 results for “Advanced” Clear

  1. SOTORASIB

    Amgen

    KRAS p.G12C Mutant Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  2. SSGJ-705

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Locally Advanced, Recurrent or Metastatic Malignancies

    phase 2 small molecule active

    2 trials

  3. SSGJ-706

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    First-line Advanced NSCLC Patients

    phase 2 small molecule active

    1 trial

  4. SSGJ-707

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Advanced/recurrent Endometrial Cancer and Platinum-resistant Ovarian Cancer

    phase 2 small molecule active

    1 trial

  5. SSGJ-707

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    First-line Advanced NSCLC Patients

    phase 2 small molecule active

    1 trial

  6. Saruparib

    AstraZeneca AB

    Advanced/Recurrent Ovarian cancer

    phase 2 small molecule active

    1 trial

  7. Saruparib, Camizestrant, Datopotamab deruxtecan, PACLITAXEL , Saruparib, DS-8201a, Saruparib, Saruparib

    AstraZeneca AB

    Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  8. Savolitinib, TAGRISSO 40 mg film-coated tablets, TAGRISSO 80 mg film-coated tablets, Savolitinib

    AstraZeneca AB

    EGFRm+ and MET+, Locally Advanced or Metastatic Non Small Cell Lung Cancer.

    phase 2 small molecule active

    1 trial

  9. Savolitinib, TAGRISSO 80 mg film-coated tablets, TAGRISSO 40 mg film-coated tablets, TAGRISSO 80 mg film-coated tablets, Savolitinib, TAGRISSO 40 mg film-coated tablets, TAGRISSO 40 mg film-coated tablets, TAGRISSO 40 mg film-coated tablets, TAGRISSO 80 mg film-coated tablets, TAGRISSO 80 mg film-coated tablets

    AstraZeneca AB

    EGFRm+ and MET+, Locally Advanced or Metastatic Non Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  10. Selinexor

    Karyopharm Therapeutics Inc

    Locally Advanced Unresectable or Metastatic Melanoma

    phase 2 small molecule terminated

    1 trial

  11. Sigvotatug vedotin, PF-08634404

    Pfizer Australia Pty Ltd

    Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  12. Sintilimab with Interleukin-2+CAPOX

    The First People's Hospital of Lianyungang

    Locally Advanced Rectal Adenocarcinoma

    phase 2 small molecule completed

    1 trial

  13. Stivarga 40 mg film-coated tablets, Tevimbra 100 mg concentrate for solution for infusion, OMTX705

    Lacuna Pharma Pty Ltd

    Advanced/metastatic colorectal cancer

    phase 2 small molecule active

    1 trial

  14. Study evaluating the efficacy of the treatment after targeting PD-L1 and TIGIT in tumors with tertiary lymphoid structures

    The George Institute

    Adult patients with a histologically confirmed TLS-positive advanced or metastatic NSCLC naïve from systemic treatment or previously treated with chemotherapy and PD1/PDL1 antagonist, and not having previously been treated with CD137 agonists or investigational immune checkpoint blockade therapies, including (but not limited) anti-TIGIT, anti-LAG3. Patients must have adequate organ function with a performance status (WHO 0-1; ECOG 0-1). Patients must not have active or history of autoimmune disease or immune deficiency. The pregnant or breastfeeding women will be excluded. Other eligibility criteria are described in the related section of the protocol.

    phase 2 other active

    1 trial

  15. Surufatinib + Serplulimab+Albumin-paclitaxel + Gemcitabine

    Sun Yat-sen University

    Locally Advanced Pancreatic Cancer

    phase 2 small molecule active

    1 trial

  16. Surzebiclimab

    BEONE MEDICINES AUS PTY LTD

    Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-in

    phase 2 small molecule completed

    1 trial

  17. Surzebiclimab

    BeiGene

    Locally Advanced or Metastatic Solid Tumors for Phase 1, Dose Escalation and Phase 2 Safety Lead-in

    phase 2 small molecule completed

    1 trial

  18. TAK-188

    Takeda

    Advanced or Metastatic Solid Tumors

    phase 2 small molecule active

    1 trial

  19. TAK-280

    Takeda

    Unresectable Locally Advanced or Metastatic Cancer

    phase 2 small molecule terminated

    1 trial

  20. TAK-280, SILTUXIMAB, TOCILIZUMAB, TOCILIZUMAB, SILTUXIMAB, TOCILIZUMAB

    Takeda

    Unresectable Locally Advanced or Metastatic Cancer

    phase 2 small molecule active

    1 trial

  21. TAK-981

    Takeda

    Advanced or Metastatic Solid Tumors

    phase 2 small molecule completed

    1 trial

  22. TAS-120

    Taiho Pharma Netherlands B.V.

    Advanced Cholangiocarcinoma

    phase 2 small molecule active

    1 trial

  23. TAZEMETOSTAT, IMFINZI 50 mg/mL concentrate for solution for infusion.

    The George Institute

    Adult participants with metastatic or unresectable locally advanced solid tumors.

    phase 2 small molecule active

    1 trial

  24. TEMOZOLOMIDE, TEMOZOLOMIDE, CAPECITABINE

    Fondazione Telethon ETS

    locally advanced rectal cancer (LARC)

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources